Abstract
Therapeutic Effect of Amlodipine Besylate in Conjunction with Enalapril Maleate Tablets in Diabetic Nephropathy and Hypertension
Department of Internal Medicine, School of Public Health, Southeast University, Nanjing, Jiangsu 210009, 1Ziyang Social Welfare Center, Ziyang, Sichuan Province 641300, China
Correspondence Address:
Jianqian Chao, Department of Internal Medicine, School of Public Health, Southeast University, Nanjing, Jiangsu 210009, China, E-mail: 18064978069@163.com
To observe the efficacy of benzenesulfonate amlodipine in conjunction with enalapril in treating female patients with diabetic nephropathy and hypertension. From August 2022 to August 2023, a total of 79 female patients diagnosed with both diabetic nephropathy and hypertension were recruited as participants for our study in the outpatient clinic. The patients were assigned randomly to either the control group (40 cases) or the observation group (39 cases). The control group was prescribed oral benzenesulfonate amlodipine tablets to manage their blood pressure, while the observation group received supplementary oral enalapril maleate tablets based on the treatment provided to the control group. The treatment regimen was administered to both groups of patients without interruption for a period of 3 mo. The study aimed to analyze and contrast the variances in blood glucose, blood pressure, and renal function markers between the two groups, while also monitoring and comparing any adverse reactions that occurred during the treatment course. No notable variations in fasting plasma glucose, postprandial 2 h blood glucose, and hemoglobin A1c were observed before and after the treatment in either group of patients, indicating no remarkable differences (p>0.05). Before treatment, there were no notable variations identified in diastolic blood pressure and systolic blood pressure between the two patient groups (p>0.05). Nevertheless, after the treatment, both groups demonstrated decreased levels of renal function indicators compared to their baseline measurements (p<0.05), and the observation group showcased notably lower levels than the control group (p<0.05). Throughout the treatment period, no remarkable disparities in the overall occurrence of adverse reactions were found between the two patient groups (p>0.05). Benzenesulfonate amlodipine in conjunction with enalapril is effective in lowering blood pressure and improving renal function in female patients with diabetic nephropathy and hypertension, and it is safe to use.
Full-Text | PDF
